Table 1.
Demographic characteristics of the 86 patients with genital psoriasis.
| Characteristics | N (%) |
|---|---|
| Number of patients | 86 |
| Male | 50/86 (58.14) |
| Age (years) | 49.81 (SD 15.16) |
| BMI | 26.7 (SD 3.16) |
| Obese (BMI≥30) | 12/86 (13.95) |
| Disease duration (years) | 14.15 (SD 10.30) |
| PsA | 15/86 (17.44) |
| Comorbidity | 31/86 (36.04) |
| Hypertension | 14/86 (16.27) |
| Diabetes | 5/86 (5.81) |
| Bio-experienced | 18/86 (20.93) |
| Anti-IL-17 | 35/86 (40.70) |
| Bimekizumab | 2/86 (2.33) |
| Brodalumab | 2/86 (2.33) |
| Ixekizumab | 26/86 (30.23) |
| Secukinumab | 5/86 (5.81) |
| Anti-IL-23 | 51/86 (59.30) |
| Risankizumab | 33/86 (38.37) |
| Guselkumab | 14/86 (16.28) |
| Tildrakizumab | 4/86 (4.65) |
SD, standard deviation; BMI, body mass index; PsA, psoriatic arthritis; IL, interleukin.